Introduction

AKAP350 (AKAP450/CG-NAP/AKAP9) is a multiple spliced A-kinase anchoring protein (AKAP), which assembles protein complexes at the Golgi apparatus and the centrosomes. Several proteins recruited to the centrosomes by this scaffold participate in the regulation of the cell cycle. Previous studies indicated that AKAP350 participates in centrosome duplication. In the present study we specifically assessed the role of AKAP350 in the progression of the cell cycle. Our results showed that interference with AKAP350 expression inhibits G1/S transition, decreasing the initiation of both DNA synthesis and centrosome duplication. We identified an AKAP350 carboxyl-terminal domain (AKAP350CTD), which contained the centrosomal targeting domain of AKAP350 and induced the initiation of DNA synthesis. Nevertheless, AKAP350CTD expression did not induce centrosomal duplication. AKAP350CTD partially delocalized endogenous AKAP350 from the centrosomes, but increased the centrosomal levels of the cyclin-dependent kinase 2 (Cdk2). Accordingly, the expression of this AKAP350 domain increased the endogenous phosphorylation of nucleophosmin by Cdk2, which occurs at the G1/S transition and is a marker of the centrosomal activity of the cyclin E-Cdk2 complex. Cdk2 recruitment to the centrosomes is a necessary event for the development of the G1/S transition. Altogether, our results indicate that AKAP350 facilitates the initiation of DNA synthesis by scaffolding Cdk2 to the centrosomes, and enabling its specific activity at this organelle. Although this mechanism could also be involved in AKAP350-dependent modulation of centrosomal duplication, it is not sufficient to account for this process.
The aim of our work was to analyze AKAP350 participation in cell cycle progression by taking advantage of specific loss-of-function studies in proliferating cells and to obtain insights into the mechanisms involved.

**Results**

**AKAP350 participates in G1/S transition**

In order to evaluate the participation of AKAP350 in cell cycle progression, we studied the effect of specifically decreasing AKAP350 expression on DNA content in HepG2 cells. Cells were transfected with a non-specific (control) and two AKAP350-specific (AKAP350KD) siRNAs. We found that the decrease in AKAP350 expression induced a 40% increase in the population of 2N-containing cells (Fig. 1A). To discriminate if this increased population corresponded to cells in G0 (quiescent) or G1 phase, we analyzed cyclin D1 levels. AKAP350KD cells showed a significant increase in cyclin D1 (Fig. 1B), thus indicating that the accumulation of 2N-containing cells was due to an increase in cells that had entered the cell cycle. We further characterized AKAP350KD cells regarding their viability. We did not find any change in the total number of viable cells, as measured by MTT assay, or in the number of dead cells, assessed by propidium iodide incorporation of non-fixed cells (data not shown), but we detected an increase in early apoptosis in AKAP350KD cells (Fig. 1C). Altogether, our results indicate that the decrease in AKAP350 expression inhibits G1/S transition, inducing G1 arrest.

**AKAP350CTD induces the initiation of DNA synthesis**

AKAP350 recruits to the centrosomes several proteins involved in G1/S transition, including PKA and Cdk2. To investigate the mechanism involved in AKAP350 participation in G1/S transition, we prepared stable cell lines expressing the AKAP350(3330–3595) domain, equivalent to AKAP450(3643–3908), fused to GFP (AKAP350CTD) or GFP (control). AKAP350CTD harbors the centrosomal targeting domain of AKAP350, the PACT domain, and the 50 amino acids located upstream the PACT domain. We first characterized two different clones (AKAP350CTD 1 and 4) for the localization of the fusion protein, and that of the endogenous AKAP350. Our results showed that AKAP350CTD localized exclusively at the centrosomes in both clones (Fig. 2A), inducing a partial displacement of the endogenous AKAP350 (Fig. 2B).

We analyzed the effect of AKAP350CTD expression on the DNA content of HepG2 cells. The expression of this AKAP350 domain induced a decrease in the population of 2N-containing cells, with a concomitant increase in 2N < x < 4N cells, both
in AKAP350CTD1 and AKAP350CTD4 cell lines (Fig. 3A). These results indicated an increase in the S phase population and a decrement of G0/G1 cells. In agreement with these results, we found that AKAP350CTD cells expressed higher levels of cyclin A (+130%, \( P < 0.01 \)) (Fig. 3B). These findings indicated that AKAP350CTD expression activated the G1/S transition. We studied if this effect was accompanied by changes in cell proliferation. Our results showed that AKAP350CTD expressing clones did not differ in the total number of viable or dead cells (Fig. 3C and D), which indicated that AKAP350CTD expression did not affect cell proliferation or death in these conditions.

AKAP350 participates in centrosomal duplication

Previous studies indicated that the expression of AKAP450(3699–3796) inhibited the initiation of centrosomal duplication,\(^ {12} \) while expression of AKAP450(2895–3908) led to centrosomal amplification.\(^ {6} \) We analyzed the effect of the specific decrease in AKAP350 expression on the number of centrosomes per cell (Fig. 4A). Our results showed that AKAP350KD cells have an increased population of cells with one centrosome with a concomitant decrease in cells with two centrosomes, which indicates that the loss of AKAP350 expression leads to the inhibition of centrosomal duplication. Considering that the initiation of DNA synthesis was also inhibited in AKAP350KD cells, and that AKAP350CTD expression was enough to promote this process, we further studied the effect of AKAP350CTD expression on centrosomal duplication. We analyzed the number of centrosomes per cell, and their extent of separation in AKAP350CTD cells. We discriminated cells containing one centrosome from those containing two attached and two separated centrosomes, which would correspond to cells in G0/G1, S, and G2/mitosis phases, respectively. No significant difference in the number of cells from each population was observed (Fig. 4B). We also did not observe centrosomal amplification in AKAP350CTD cells. Thus, the expression of AKAP350CTD was capable of inducing the initiation of DNA synthesis, but not centrosomal duplication. These results indicated that, while AKAP350 participation in DNA synthesis lies in its carboxyl-terminal domain, there are other fragments of the molecule involved in the modulation of centrosomal duplication.

AKAP350CTD increases centrosomal Cdk2 activity

Among the proteins involved in G1/S transition and centrosomal duplication, Cdk2 interacts with AKAP450(2895–3908),\(^ {6} \) while PKA has two different interaction motifs located at positions 1439–1456 and 2551–2565 of the AKAP450 sequence,\(^ {1, 4} \) which are excluded from AKAP350CTD. Immunofluorescence analysis indicated that Cdk2 localizes at the centrosomes both in control and AKAP350CTD cells (Fig. 5A), but was not suitable for quantitative analysis (see Materials and Methods). Therefore, we investigated if AKAP350CTD affected the centrosomal localization of Cdk2 by analyzing Cdk2 expression in centrosome-enriched subcellular fractions. We found that AKAP350CTD expression did not induce any change in total Cdk2 expression, but increased centrosomal Cdk2 levels (Fig. 5B). We further studied AKAP350CTD effects on centrosomal activity of Cdk2 by determining the phosphorylation status of its centrosomal substrate nucleophosmin (NPM). NPM is a well-characterized centrosomal target of cyclin E-Cdk2, whose phosphorylation promotes the initiation of centrosomal duplication.\(^ {16} \) We analyzed NPM phosphorylation at its specific Cdk2 site, and found that the expression of AKAP350CTD induced an increase in NPM phosphorylation by Cdk2 (Fig. 6).

Discussion

Previous studies demonstrated the participation of AKAP350 in centrosomal duplication.\(^ {6, 12} \) The first of these studies showed that the expression of the PACT domain induced abrogation of cell cycle progression either in G2 phase or in G1 phase, in HeLa
or RPE1 cells, respectively. On the other hand, the second study found that the expression of AKAP450(2895–3908) did not induced any change in the cell cycle distribution of CHO cells. The differences between these studies may lay in two different facts: First, the AKAP350 domains used affect differentially the localization of the endogenous protein. Second, both constructs interact with different cell cycle proteins. Therefore, although these studies supported the concept that AKAP350 participates in the modulation of cell cycle progression, it was not clear which effects were secondary to endogenous AKAP350 delocalization, and which to the presence of its derived fusion protein at the centrosomes.

We first studied the effect of specifically decreasing AKAP350 expression by RNA interference on the cell cycle distribution of HepG2 cells. We found that the decrease in AKAP350 levels increases the G0/G1 population. We have previously demonstrated that the reduction in AKAP350 expression inhibits HepG2 cells differentiation, thus suggesting that the increase in 2N-containing cells was due to an increase in G1, and not in G0 cells. The entrance into the cell cycle, from G0 to G1, is accompanied by an increase in cyclin D1 levels. We found that cyclin D1 levels were increased in AKAP350KD cells, thus confirming that these cells entered the cell cycle, but could not progress to S phase.

Previous data indicated that disruption of centrosomes by decreasing different centrosomal proteins leads to G1 arrest in cells with wild-type p53. Our own experiments performed in HepG2 cells, which express functional p53, demonstrated that the increase in G1 events in AKAP350KD cells was accompanied by an activation of apoptosis, which is consistent with induction of G1 arrest. We investigated if the effect of AKAP350 knock down on the cell cycle was a general effect, due to a non-specific effect on centrosomal integrity, or if AKAP350 specifically participated in G1/S transition. We prepared HepG2 cell lines with stable centrosomal expression of an AKAP350 carboxyl-terminal domain, which induced a partial displacement of the endogenous protein. Instead of mimicking AKAP350 knock down effect, the expression of this fragment of the protein lead to an increase in cells with DNA content corresponding to S phase, accompanied by a rise in cyclin A levels. Therefore, AKAP350CTD expression...
was enough to induce the G1/S transition, revealing a specific role of AKAP350 in this process.

The Cdk2 recruitment to centrosomes is a critical event during G1/S transition.15 Previous studies demonstrate that expression of the AKAP450 (2895–3908) domain increases the centrosomal levels of this mitotic kinase. Thus, we further evaluated if AKAP350CTD, equivalent to AKAP450 (3643–3908), participates in the centrosomal recruitment of Cdk2. AKAP350CTD expression induced an increase in Cdk2 protein levels at the centrosome. Although Cdk2 activity is primarily modulated by its interaction with inhibitors, such as p21 or p17, or activators, such as cyclin E and cyclin A, other signaling proteins can further modulate this kinase. In fact, AKAP350 interacts with two proteins which can regulate the G1/S transition by coordinating the activity of both DNA synthesis and centrosomal duplication. On one hand, by means of its carboxyl-terminal domain, AKAP350 enables Cdk2 activity at the centrosomes at this stage of the cell cycle, therefore stimulating the initiation of DNA synthesis. Although the facilitation of Cdk2 activity would also be involved in promoting centrosomal duplication, the recruitment of other signaling proteins by different AKAP350 domains is likewise necessary for this process to be initiated.

Materials and Methods

Cell culture

HepG2 cells (ATCC) were grown on plastic dishes in DMEM medium, as previously described.10

Reduction of AKAP350 expression by interfering RNA

In order to reduce AKAP350 expression, two specific 21 nucleotide double chain RNA (siRNA), siRNA1 and siRNA2, and a scrambled control were designed as we previously described,10 and synthesized using an Ambion commercial kit "SilencerTM siRNA". HepG2 cells were transfected using Dharmafect 4 reagent (Thermo Fisher Scientific), as we previously described.10 Experiments were performed 48 h after transfection, and the specific decrease in AKAP350 expression was confirmed by immunoblotting.

Generation of stable cell lines (AKAP350CTD1 and AKAP350CTD4)

The AKAP350 (3330–3595) domain, equivalent to AKAP450 (3643–3908), was cloned into pEGFP-C2 (Clontech) generating a construct coding for GFP fused to the carboxy-terminal domain of AKAP350 (AKAP350CTD-GFP). We generated populations of HepG2 cells which stably express AKAP350CTD-GFP or GFP (control). HepG2 cells were

Figure 4. AKAP350KD, AKAP350CTD, and control cells were fixed and stained with γ-tubulin and DAPI. Centrosomes were identified as punctate structures enriched in γ-tubulin. Images were quantified by grouping cells as one-centrosome and two-centrosome cells. (A) The bars represent mean values of cells transfected with a control, or two different specific siRNAs (AKAP350KD 1 and 2). (B) When analyzing AKAP350CTD cells, two-centrosome cells were further categorized in cells containing the centrosomes together (T) or separated (S), depending whether the distance between them was smaller or greater than 2 µm, respectively. Results are means ± s.e.m. of three independent experiments. *P < 0.05.
transfected by electroporation, as previously described. After 24 h, the antibiotic Geneticin (Invitrogen, 500 μg/ml) was added to the media in order to select the transfected cells. For the maintenance of these cell lines, they were grown in a medium containing Geneticin 200 μg/ml in conditions otherwise similar to parental cells.

**Cell viability and proliferation studies**

**Metabolic activity assessment (MTT assay)**

Cells were cultured in 96-well microplates and methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma-Aldrich) was added into the culture medium at different time points, as we previously described. After 2 h, cells were lysed by addition of DMSO and absorbance of the metabolite produced from viable cells was detected at 540 nm in a microplate reader (Beckman Coulter LD400). Results were expressed as percentage of absorbance in control cells.

**Annexin V/propidium iodide assay**

Cells were detached from the petri dishes, gently homogenized in the culture medium/PBS and harvest. Apoptotic externalization of phosphatidylserine and cell death was assayed by staining with Annexin V-FITC and propidium iodide (Sigma Aldrich) or with Annexin V-PE and 7-Animo-Actinomycin (BD Biosciences), for cells expressing GFP associated fluorescence, coupled to flow cytometric analysis (Cell Sorter BD FACSAria II, BD Biosciences), following the manufacturer’s instructions.

**Cell cycle analysis by flow cytometry**

Cell distribution in the cell cycle was analyzed by determining the cellular DNA content by flow cytometry. 1 × 10^6 cells were fixed with cold 70% ethanol and then washed with PBS and marked with 50 μg/ml propidium iodide in a buffer containing 0.1% sodium citrate, 0.02 mg/ml RNA, and 0.3% NP-40. Results were analyzed using WinMDi and CellCycle programs.

**Immunoblotting**

Cells were washed with cold phosphate buffered saline (PBS), scraped, and pelleted at 200 g for 5 min at 4 °C. Pelleted HepG2 cells were resuspended in Triton X-100 1%/PBS pH 7.4 with protease and phosphatase inhibitors and subjected to two freeze-thaw cycles. Lysates were centrifuged at 1000 g for 5 min and the clear supernatants were conserved. Total protein concentrations were measured according to Lowry et al. Solubilized membranes were heated 10 min at 70 °C in sample buffer (20 mM Tris, pH 8.5, 1% SDS, 400 μM DTT, 10% glycerol). Samples containing equal amounts of proteins were subjected to SDS 4%/10% discontinuous or 12% PAGE. The proteins in the 4% gel were transferred to nitrocellulose membranes (Amersham Pharmacia), while 12% gel proteins were transferred to polyvinyl difluoride

**Figure 5.** Effect of AKAP350CTD expression on centrosomal levels of Cdk2. (A) AKAP350CTD and control cells were cultured for 24 h and fixed with methanol. Fixed cells were double-stained for Cdk2 and γ-tubulin, and analyzed by confocal microscopy. The first and second column show images of the channels corresponding to γ-tubulin and Cdk2, and the third column the overlay view in RGB mode of the channels corresponding to GFP expression (green) and γ-tubulin (blue) and Cdk2 (red) staining. Bar, 10 μm. Arrows indicate centrosomes with orthogonal views. (B) Centrosomal enriched fractions (CF) were prepared as described in Materials and Methods, and Cdk2 levels at CF and at the starting material (SM) analyzed by western blot. γ-tubulin was used as loading control. Bars show the percentage of Cdk2 recovered at CF. Results are mean ± s.e.m of 4 independent experiments. *P < 0.05.

**Figure 6.** Effect of AKAP350CTD expression on centrosomal activity of Cdk2. NPM and NPM(T199P) (PNPM) levels were analyzed by immunoblotting in control and AKAP350CTD cells. Bars represent the ratio of the density of the PNPM band, divided by that corresponding to total NPM expression. Results are mean ± s.e.m of three independent experiments. *P < 0.05.
membranes (Perkin Elmer Life Sciences). Blots were blocked with 5% non-fat milk in PBS/0.3% Tween 20. Nitrocellulose membranes were probed with the monoclonal mouse antibody anti-AKAP350 (14G2) (1:500) and polyvinylidifluoride membranes were probed with primary rabbit antibodies: anti-β-actin (1:2000, Sigma-Aldrich), anti-α-tubulin (1:2000, Sigma-Aldrich), and anti-Cyclin D1 (1:400, Santa Cruz Biotechnology). The blots were washed and incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies. Bands were detected by chemiluminescence reaction (Amersham Pharmacia), after exposition to Kodak XAR film. Bands were quantified using the Image J program. In preparing the figures, brightness and contrast were adjusted in order to improve visualization.

**Immunofluorescence and confocal microscopy**

The cells were grown on glass coverslips and, at the end of each experiment, washed with PBS and fixed with 4% paraformaldehyde or in 100% methanol. Fixed cells were permeabilized and blocked with 0.3% Triton X-100/bovine serum albumin 1%/PBS, pH 7.4 for 10 min. For Cdk2 detection, cells were processed as previously described. They were incubated with rabbit anti-Cdk2 (1:100) and mouse anti-γ-tubulin (1:500) or anti-AKAP350 (1:80) antibodies for 2 h at room temperature. The coverslips were washed, incubated with the secondary Alexa 555 and Cy5 conjugated antibodies and with 4′,6-diamidino-2-phenylindole (DAPI) and mounted with ProLong, as previously described. Fluorescence localization was detected by confocal laser microscopy (Nikon C1SiR with inverted microscope Nikon TE200). Serial optical 0.3 μm thick sections were collected in the z-axis. Z-stacks were built, and projections were obtained using Image J tools. In preparing the figures, adjustment in brightness and contrast were equally applied to the entire images using Adobe Photoshop software, in order to improve visualization of fluorescence.

**Morphometric analysis of centrosomes**

A morphometric analysis was performed on the images obtained by confocal microscopy in order to determine centrosome number and localization. γ-tubulin staining was used to identify centrosomes. Images were quantified by grouping cells in the following categories: one-centrosome cells and two-centrosome cells, considering the centrosomes attached or separated, depending on whether the distance between centrosomes was smaller/equal or greater than 2 μm. At least 150 cells were analyzed in each group.

**Analysis of protein localization in centrosomes**

Centrosomal localization of AKAP350 by confocal microscopy was performed as we have previously described. As regards Cdk2, due to the extraction step performed prior to fixation and to its predominant nuclear localization, we found this method inappropriate to estimate its centrosomal localization. Alternatively, we prepared centrosome-enriched fractions by centrifugation in a discontinuous sucrose gradient, using a method based on Moudju and Bornens, modified to improve centrosomal proteins resolution. Cells were gently sonicated in cold buffer containing 80 mM HEPES (pH 6.8), 100 mM KCl, 14% sucrose, 1 mM MgCl2, 1 mM EGTA, and protease inhibitors. In order to eliminate unbroken cells and nuclear fractions, cell extracts were centrifuged at 1500 g for 15 min. The supernatant was brought to 20% sucrose, 0.1% Triton X-100, and loaded on the top of a sucrose step gradient consisting of 70% and 40% steps. Samples were centrifuged at 100 000 g for 20 min and 6 fractions corresponding to the 40–70% sucrose fractions were collected. The best enrichment in centrosomes, assessed by γ-tubulin distribution, was obtained at the fraction corresponding to the 40–70% interface, and the 70% step bottom fraction.

**Statistical analysis**

Data are expressed as mean ± s.e.m. A paired Student t test was used for comparison between groups and non-parametric Mann–Whitney test was used for comparisons within each experiment. P < 0.05 was considered statistically significant.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

This work was supported by CONICET and ANPCyT grants (PIP 0652 and PICTs 01865 and 2012-2198) to MCL and by the NIH grant R01 DK043405 to JRG. We thank A Ensinck, Dr CE Banchio, and Dr RA Marinelli (University of Rosario) for support and critical discussion.

**References**

1. Schmidt PH, Dransfield DT, Claudio JO, Hawley RG, Trotter KW, Milgram SL, Goldenzing JR. AKAP350, a multiply spliced protein kinase A-anchoring protein associated with centrosomes. J Biol Chem 1999; 274:3055-66; PMID:9915845; http://dx.doi.org/10.1074/jbc.274.5.3055
2. Takahashi M, Shibata H, Shimakawa M, Miyamoto M, Mukai H, Ono Y. Characterization of a novel giant scaffolding protein, CG-NAP, that anchors A-anchoring protein associated with centrosomes. J Biol Chem 1999; 274:17267-74; PMID:10358886; http://dx.doi.org/10.1074/jbc.274.24.17267
3. Winczek O, Skúlísegg BS, Kærer G, Bornens M, Taskén K, Jahnsen T, Ostervick S. Cloning and characterization of a cDNA encoding an A-kinase anchoring protein located in the centrosome, AKAP450. EMBO J 1999; 18:1858-68; PMID:10202149; http://dx.doi.org/10.1093/emboj/18.7.1858
4. Sumishyoo E, Sugimoto A. Cell polarity: centrosomes were smaller/equal or greater than 2 μm. At least 150 cells were analyzed in each group.

5. Osmani A, Gudgeon TT, Taskén K, Jahnsen T, Ostervick S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2003; 4:686-8; PMID:15133726; http://dx.doi.org/10.1038/35089575
6. Nishimura T, Takahashi M, Kim HS, Mukai H, Ono Y. Centrosome-targeting region of CG-NAP causes centrosome amplification by recruiting cyclin E-cdk2 complex. Genes Cells 2005; 10:75-86; PMID:15670215; http://dx.doi.org/10.1111/j.1365-2443.2005.00816.x
7. Kærer G, Di Fiore B, Celavi C, Lehtrick KF, Mogensen M, Delouvee A, Lavia P, Bornens M, Tassin AM. Part of Ran is associated with AKAP450 and its organizing activity. Mol Biol Cell 2003; 14:4260-71; PMID:1457334; http://dx.doi.org/10.1091/mbc. E02-11-0773
8. Takahashi M, Yamagiwa A, Nishimura T, Mukai H, Ono Y. Centrosomal proteins CG-NAP and kendrin provide microtubule nucleation sites by anchoring gamma-tubulin ring complex. Mol Biol Cell 2002; 13:3235-45; PMID:12221128; http://dx.doi.org/10.1091/mbc.E02-02-0112

9. Rivero S, Cardenas J, Bornens M, Rios RM. Microtubule nucleation at the cis-side of the Golgi apparatus requires AKAP450 and GM130. EMBO J 2009; 28:1016-28; PMID:19242490; http://dx.doi.org/10.1038/emboj.2009.47

10. Martaloni SM, Kolobova E, Favre C, Marrelli RA, Goldenring JR, Larocca MC. AKAP350 Is involved in the development of apical “canalicular” structures in hepatic cells HepG2. J Cell Physiol 2012; 227:160-71; PMID:21374596; http://dx.doi.org/10.1002/jcp.22713

11. Gillingham AK, Munro S. The PACT domain, a conserved centrosomal targeting motif in the coiled-coil proteins AKAP450 and pericentrin. EMBO Rep 2000; 1:524-9; PMID:11263498

12. Keryer G, Witczak O, Delouvee A, Kemmner WA, Rouillard D, Tasken K, Bornens M. Dissociating the centrosomal matrix protein AKAP450 from centrioles impairs centriole duplication and cell cycle progression. Mol Biol Cell 2003; 14:2436-46; PMID:12808041; http://dx.doi.org/10.1091/mbc.E02-09-0614

13. Mardin BR, Schiebel E. Breaking the ties that bind: new advances in centrosome biology. J Cell Biol 2012; 197:11-8; PMID:22472457; http://dx.doi.org/10.1083/jcb.201108086

14. Lacey KR, Jackson PK, Stavens T. Cyclin-dependent kinase control of centrosome duplication. Proc Natl Acad Sci U S A 1999; 96:2817-22; PMID:10077594; http://dx.doi.org/10.1073/pnas.96.6.2817

15. Ferguson RL, Maller JL. Centrosomal localization of cyclin E-Cdk2 is required for initiation of DNA synthesis. Curr Biol 2010; 20:856-60; PMID:20399658; http://dx.doi.org/10.1016/j.cub.2010.03.028

16. Okuda M, Horn HF, Tatrapole P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103:127-40; PMID:11051555; http://dx.doi.org/10.1016/S0092-8674(00)00993-3

17. Mikule K, Delaval B, Kaldas P, Jurczyk A, Hergert P, Doxsey S. Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nat Cell Biol 2007; 9:160-70; PMID:17330329; http://dx.doi.org/10.1038/ncb1529

18. Sayan AE, Sayan BS, Findikli N, Ortuuk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 2001; 20:5111-7; PMID:11526499; http://dx.doi.org/10.1038/sj.onc.1204669

19. Choi J, Chiang A, Taulier N, Gros R, Pirani A, Husain M. A calmodulin-binding site on cyclin E mediates Ca2+ -sensitive G1/S transition in vascular smooth muscle cells. Circ Res 2006; 98:1273-81; PMID:16627785; http://dx.doi.org/10.1161/01.RES.0000223459.19250.91

20. Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC. Cyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent cell cycle arrest. Exp Cell Res 2006; 312:4181-204; PMID:17123531; http://dx.doi.org/10.1016/j.yexcr.2006.09.023

21. Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, DePaoli-Roach AA, Horne MC. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B’ subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem 2002; 277:27449-67; PMID:121956189; http://dx.doi.org/10.1074/jbc.M111693200

22. Lutz W, Lingle WL, McCormick D, Greenwood TM, Salisbury JL. Phosphorylation of centrin during the cell cycle and its role in centriole separation preceding centrosome duplication. J Biol Chem 2001; 276:20774-80; PMID:11279195; http://dx.doi.org/10.1074/jbc.M101324200

23. Ferrerri AC, Martaloni SM, Ochoa JE, Larocca MC, Favre C. Protein kinase A signals apoptotic activation in glucose-deprived hepatocytes: participation of reactive oxygen species. Apoptosis 2012; 17:475-91; PMID:22270152; http://dx.doi.org/10.1007/s10495-012-0697-2

24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75; PMID:14907713

25. Moudjou M, Bornens M. Isolation of centrosomes from cultured animal cells, in Celis JE (Ed.), Cell Biology: A Laboratory Handbook. San Diego:Academic Press, 1994: 595–604.

26. Miotz M, Braunfeld MB, Fung JC, Sedat JW, Alberts BM, Agard DA. Three-dimensional structural characterization of centrosomes from early Drosophila embryos. J Cell Biol 1995; 130:1149-59; PMID:7657699; http://dx.doi.org/10.1083/jcb.130.5.1149